Market Closed -
Nasdaq
16:00:00 2024-06-17 EDT
|
5-day change
|
1st Jan Change
|
1.7
USD
|
-3.41%
|
|
-6.08%
|
-14.14%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
475.7
|
210.6
|
569.9
|
264.3
|
160.7
|
138.8
|
-
|
-
|
Enterprise Value (EV)
1 |
367.6
|
210.6
|
410.2
|
169
|
160.7
|
138.8
|
138.8
|
138.8
|
P/E ratio
|
-6.6
x
|
-3.69
x
|
-7.38
x
|
-3.75
x
|
-5.18
x
|
-3.94
x
|
-3.81
x
|
-3.55
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
226
x
|
18.2
x
|
210
x
|
50.8
x
|
15.5
x
|
6.01
x
|
7.64
x
|
10.6
x
|
EV / Revenue
|
226
x
|
18.2
x
|
210
x
|
50.8
x
|
15.5
x
|
6.01
x
|
7.64
x
|
10.6
x
|
EV / EBITDA
|
-
|
-
|
-9.18
x
|
-3.92
x
|
-5.02
x
|
-2.47
x
|
-1.82
x
|
-1.59
x
|
EV / FCF
|
-9.72
x
|
-3.71
x
|
-19.3
x
|
-3.52
x
|
-
|
-6.09
x
|
-6.4
x
|
-2.43
x
|
FCF Yield
|
-10.3%
|
-27%
|
-5.18%
|
-28.4%
|
-
|
-16.4%
|
-15.6%
|
-41.2%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
48,004
|
50,146
|
71,155
|
71,435
|
81,157
|
81,662
|
-
|
-
|
Reference price
2 |
9.910
|
4.200
|
8.010
|
3.700
|
1.980
|
1.700
|
1.700
|
1.700
|
Announcement Date
|
20-02-26
|
21-02-25
|
22-02-24
|
23-03-29
|
24-03-13
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
2.103
|
11.56
|
2.712
|
5.202
|
10.4
|
23.11
|
18.17
|
13.14
|
EBITDA
1 |
-
|
-
|
-62.06
|
-67.38
|
-32.04
|
-56.27
|
-76.35
|
-87.19
|
EBIT
1 |
-62.49
|
-51.79
|
-64.7
|
-70.11
|
-34.78
|
-43.49
|
-46
|
-59.96
|
Operating Margin
|
-2,971.8%
|
-448.24%
|
-2,385.94%
|
-1,347.69%
|
-334.48%
|
-188.17%
|
-253.17%
|
-456.34%
|
Earnings before Tax (EBT)
1 |
-61.59
|
-56.83
|
-69.64
|
-70.19
|
-30.37
|
-33.91
|
-33.72
|
-48.53
|
Net income
1 |
-61.44
|
-56.93
|
-69.71
|
-70.54
|
-30.7
|
-36.96
|
-33.72
|
-48.53
|
Net margin
|
-2,921.88%
|
-492.65%
|
-2,570.75%
|
-1,355.91%
|
-295.21%
|
-159.91%
|
-185.6%
|
-369.36%
|
EPS
2 |
-1.501
|
-1.137
|
-1.086
|
-0.9858
|
-0.3821
|
-0.4316
|
-0.4462
|
-0.4793
|
Free Cash Flow
1 |
-48.96
|
-56.78
|
-29.52
|
-74.98
|
-
|
-22.81
|
-21.7
|
-57.23
|
FCF margin
|
-2,328%
|
-491.38%
|
-1,088.51%
|
-1,441.4%
|
-
|
-98.66%
|
-119.4%
|
-435.57%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20-02-26
|
21-02-25
|
22-02-24
|
23-03-29
|
24-03-13
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
0.5023
|
1.402
|
1.15
|
1.035
|
1.422
|
0.7578
|
1.359
|
1.472
|
6.786
|
5.021
|
11.16
|
2.845
|
4.63
|
8.488
|
7.25
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-6.049
|
-7.956
|
-13.7
|
-14.4
|
-15.12
|
-
|
-
|
EBIT
1 |
-19.6
|
-17.8
|
-16.1
|
-19.78
|
-13.39
|
-10.21
|
-9.636
|
-7.939
|
-6.844
|
-8.701
|
-11.47
|
-12.07
|
-8.957
|
-5.354
|
-6.023
|
Operating Margin
|
-3,902.72%
|
-1,268.91%
|
-1,400.09%
|
-1,910.78%
|
-941.2%
|
-1,347.06%
|
-708.85%
|
-539.49%
|
-100.85%
|
-173.28%
|
-102.76%
|
-424.33%
|
-193.44%
|
-63.07%
|
-83.08%
|
Earnings before Tax (EBT)
1 |
-20.61
|
-15.17
|
-14.99
|
-24.43
|
-12.34
|
-9.627
|
-8.77
|
-5.866
|
-5.981
|
-8.248
|
-9.574
|
-10.14
|
-5.123
|
-5.021
|
-5.735
|
Net income
1 |
-20.61
|
-15.17
|
-15.23
|
-24.52
|
-12.34
|
-9.712
|
-8.741
|
-6.133
|
-5.986
|
-8.251
|
-11.5
|
-11.56
|
-8.332
|
-5.021
|
-5.735
|
Net margin
|
-4,103.85%
|
-1,081.8%
|
-1,324.47%
|
-2,368.45%
|
-867.25%
|
-1,281.64%
|
-643.04%
|
-416.79%
|
-88.22%
|
-164.33%
|
-103.03%
|
-406.35%
|
-179.94%
|
-59.15%
|
-79.11%
|
EPS
2 |
-0.2941
|
-0.2101
|
-0.2148
|
-0.3417
|
-0.1733
|
-0.1196
|
-0.1094
|
-0.0752
|
-0.0764
|
-0.0970
|
-0.1184
|
-0.1186
|
-0.0970
|
-0.0810
|
-0.1025
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
22-02-24
|
22-05-05
|
22-08-04
|
22-11-09
|
23-03-29
|
23-05-16
|
23-08-03
|
23-11-07
|
24-03-13
|
24-05-09
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
108
|
-
|
160
|
95.3
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-49
|
-56.8
|
-29.5
|
-75
|
-
|
-22.8
|
-21.7
|
-57.2
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-72.1%
|
-72.6%
|
-
|
-128%
|
-1,008%
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.64
|
1.09
|
0.54
|
0.77
|
-
|
2.24
|
2.46
|
2.95
|
Capex / Sales
|
30.31%
|
9.46%
|
19.88%
|
14.74%
|
-
|
9.68%
|
13.54%
|
22.48%
|
Announcement Date
|
20-02-26
|
21-02-25
|
22-02-24
|
23-03-29
|
24-03-13
|
-
|
-
|
-
|
Average target price
4.1
USD Spread / Average Target +141.18% Consensus |
1st Jan change
|
Capi.
|
---|
| -14.14% | 139M | | +16.42% | 122B | | +19.02% | 113B | | +2.94% | 22.66B | | -16.20% | 21.34B | | -39.57% | 16.92B | | -11.63% | 16.68B | | -16.31% | 16.61B | | +2.68% | 13.62B | | +21.16% | 11.04B |
Bio Therapeutic Drugs
|